Type ? Target CGRPR Legal status Investigational | Source Humanized ATC code None CAS Number 1644539-04-7 | |
Eptinezumab (formerly ALD403) is an experimental drug being developed by Alder Biopharmaceuticals for the treatment of migraine. It is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP) as an antagonist. It is currently in Phase III clinical trials.
References
Eptinezumab Wikipedia(Text) CC BY-SA